RKTO (Rocket One Inc.) stock: $0.79, $19.7M market cap, $7.9M cash, $11.8M EV, $25.2M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
HT-001
Phase 2 · Active Modality: topical formulation
Partnerships George Washington University: patent license (Feb 2020)
Indications- EGFR-inhibitor skin disorders (Phase 2)
Status note Lead program. IND cleared Dec 2022 for Phase 2a as concomitant therapy with EGFR inhibitors; EMA approval Jan 2026 to expand to Spain, Poland and Hungary; enrolling open-label and double-blind randomized cohorts.
BioLexa
Phase 1 · Active Modality: topical (zinc chelator + gentamicin)
Target biofilm
Partnerships University of Cincinnati: exclusive license (BioLexa Platform)
Indications- Atopic dermatitis (eczema) (Phase 1)
Status note Phase 1b in Australia completed (final dosing Sep 2022); company does not anticipate further trials in Australia. No discontinuation disclosed.
HT-KIT
Preclinical · Active Modality: n/a
Target KIT
Partnerships NC State: exclusive worldwide license
Indications- Mast cell neoplasms / mastocytosis (Preclinical)
- Anaphylaxis (Preclinical)
Status note Preclinical; IND-enabling activities underway (analytical and animal toxicology). Orphan Drug Designation for mastocytosis (Mar 2022); pre-IND meeting held Sep 2023.
HT-004
Preclinical · Active Modality: oligonucleotide (exon-skipping)
Target IgE
Partnerships NC State: exclusive license
Indications- Asthma (Preclinical)
- Allergies (Preclinical)
Status note Preclinical; proof-of-concept studies completed in humanized mouse models; further studies ongoing at NC State. Inhalational administration.
HT-ALZ
Preclinical · Active Modality: n/a
Target NK-1R
Partnerships Washington University in St. Louis: sponsored research agreement
Indications- Alzheimer's disease (Preclinical)
Status note Preclinical; formulation prototypes in development; additional animal studies planned before a pre-IND submission.
HT-VA
Preclinical · Active Modality: n/a
Target GDNF receptor
Partnerships U.S. Department of Veterans Affairs: exclusive license (Dec 2024); Cooperative Research and Development Agreement
Status note Preclinical proof-of-principle studies under VA CRADA.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.